Details for Patent: 11,504,370
Which drugs does patent 11,504,370 protect, and when does it expire?
Patent 11,504,370 protects TUKYSA and is included in one NDA.
This patent has sixty-six patent family members in thirty countries.
Summary for Patent: 11,504,370
| Title: | Treatment of brain cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Patrice A. Lee, Shannon L. Winski, Kevin Koch | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Array Biopharma Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/402,068 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 11,504,370: Tucatinib Brain-Metastases Claims, Scope, Validity and Patent LandscapeUS Patent 11,504,370 protects specific treatment methods using tucatinib, trastuzumab and capecitabine for breast-cancer patients with brain metastases. The strongest claim coverage is directed to the HER2-positive population previously treated for breast cancer, including patients previously treated with trastuzumab. The patent does not claim tucatinib as a chemical entity, trastuzumab, capecitabine, or the combination as a composition of matter. It claims clinical use of the three-drug regimen. The patent is commercially important because it maps closely to the HER2CLIMB treatment regimen that supported FDA approval of Tukysa (tucatinib) for HER2-positive unresectable advanced or metastatic breast cancer, including patients with brain metastases.[1,2] What drug does US Patent 11,504,370 cover?The lengthy chemical name in the claims identifies tucatinib, also known as ONT-380 and marketed in the United States as Tukysa.
The claims use the older “ErbB2-positive” terminology. In clinical and regulatory materials, the same population is generally described as HER2-positive. What are the independent claims in US 11,504,370?Claims 1 and 8 are the two independent claims. Claim 1: HER2-positive brain-metastases populationClaim 1 requires all of the following:
Claim 1 is therefore a regimen claim limited to a biomarker-defined metastatic breast-cancer population. It does not cover tucatinib monotherapy or tucatinib combined with an unrelated HER2-directed agent. Claim 8: broader breast-cancer brain-metastases populationClaim 8 covers:
Claim 8 does not expressly require HER2-positive disease. Claim 9 narrows claim 8 by adding the ErbB2-positive limitation. The relationship between claims 1 and 8 gives the patent two principal coverage positions:
The broader wording of claim 8 may face greater enablement, written-description and obviousness scrutiny than claim 1 because it is not expressly restricted to HER2-positive disease. Commercial use, however, is most closely aligned with the narrower HER2-positive claims. How do the dependent claims narrow the patent scope?The dependent claims add treatment history, dosage form and dose limitations. Prior treatment limitationsClaims 2, 3, 10 and 11 require prior treatment for breast cancer. Claims 3 and 11 specifically require prior trastuzumab treatment. These limitations are commercially relevant because the approved Tukysa indication is directed to patients with advanced or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting.[1] A patient treated with tucatinib earlier in the treatment sequence may fall outside claims requiring prior trastuzumab, depending on the actual treatment history. Oral administrationClaims 4, 6, 12 and 14 require tucatinib to be administered in an oral dosage form. This excludes a nonoral tucatinib formulation if one were developed and administered without satisfying the oral-dosage limitation. The oral limitation is not restrictive for current commercial use because Tukysa is supplied as oral tablets. Dose rangeClaims 5, 7, 13 and 16 specify approximately 100 mg to 1,600 mg per day. The supplied text contains typographical defects, including “100 m” in claim 5. The surrounding claims use “mg,” and the intended unit is evidently milligrams. The claimed range is substantially broader than the labeled adult Tukysa regimen of 300 mg orally twice daily, or 600 mg per day.[1] The 600 mg daily dose falls within the claimed range. Solid dispersion and tablet limitationsClaim 15 requires a solid-dispersion oral dosage form. Claim 16 refers to administration of “the tablet” within the stated dose range. These claims are narrower than claim 14 because they require a specific formulation architecture. They may be relevant to a generic applicant or licensee that uses the same solid-dispersion technology, but they do not necessarily cover every oral tucatinib tablet. What formulations are protected by US 11,504,370?The patent has limited formulation coverage. Its formulation-related claims require:
The patent does not appear, based on the supplied claims, to claim:
The practical infringement question is whether a competing product is administered as part of the claimed regimen, not merely whether its tablet has a similar appearance or contains tucatinib. Does the patent cover tucatinib monotherapy?No. Each independent claim requires tucatinib to be administered in combination with both trastuzumab and capecitabine. A product administered as tucatinib monotherapy would not literally satisfy claims 1 or 8. A regimen combining tucatinib with trastuzumab but not capecitabine would also omit an express limitation. The same applies to tucatinib plus capecitabine without trastuzumab. This combination requirement materially narrows the patent compared with a patent claiming tucatinib treatment generally. What is the likely infringement risk for generic tucatinib?A generic tucatinib product could face a method-of-use issue if its proposed labeling directs use in the patented triple regimen for patients with brain metastases.
Under 35 U.S.C. § 271(b), a company can face induced-infringement allegations if it actively encourages infringement. A “skinny label” may reduce risk for a carved-out indication, but it does not automatically eliminate liability where marketing, clinical materials or product instructions encourage the patented use.[3] The claims also require administration to a patient. Sale of tucatinib alone is not necessarily direct infringement of these method claims. The risk shifts toward induced infringement, contributory infringement and infringement allegations against healthcare providers or institutions that administer the full regimen. What is the Orange Book status of US Patent 11,504,370?Tukysa is approved under NDA 213055. FDA Orange Book listings determine whether a patent is formally listed against the NDA and whether an applicant must address it in an ANDA certification.[4] A complete commercial assessment must distinguish among:
US 11,504,370 is a method-of-treatment patent associated with tucatinib’s clinical use. Its practical value depends heavily on whether it is listed in the current Orange Book for NDA 213055 and whether the FDA accepted the listed use code. Orange Book status can change through listing corrections, delisting, patent expiration and FDA review of listing eligibility. A Paragraph IV certification against a listed patent would require the ANDA applicant to assert that the patent is invalid, unenforceable or not infringed. A Paragraph III certification would defer approval until patent expiration. A section viii statement may be available where the applicant omits the patented method from its labeling, subject to the scope of the approved indication and the applicant’s proposed labeling.[5] When does tucatinib lose patent and regulatory exclusivity?The patent’s exact expiration date cannot be inferred reliably from the grant date alone. The relevant calculation depends on the earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers and any patent-term extension. For tucatinib, the exclusivity stack may include:
The key business point is that a generic may be blocked by a composition or formulation patent even if US 11,504,370 is avoided. Conversely, expiration of a composition patent would not necessarily eliminate risk under an unexpired method patent. How strong is the patent estate for tucatinib?The estate is strongest where multiple rights converge on the commercial product:
US 11,504,370 is narrower than a composition patent because it requires a particular disease, treatment setting and combination. Its strength is increased by the close match between the claimed regimen and the FDA-approved clinical use. Potential validity pressure points include:
The exact chemical identification of tucatinib is a strength against ambiguity. The regimen and patient-selection limitations are clear enough to provide a focused enforcement theory, although claim 8 is materially broader than claims 1 and 9. What patent litigation and Paragraph IV challenges affect tucatinib?The supplied record does not identify a specific Paragraph IV lawsuit, ANDA filer, settlement agreement or final judgment involving US 11,504,370. No litigation conclusion should be drawn solely from the patent’s issuance or Orange Book association. A complete litigation review would normally examine:
The principal potential challengers would be generic manufacturers seeking approval of tucatinib tablets, including companies with oncology solid-dose manufacturing capabilities. Biosimilar companies are not the primary threat to this patent because trastuzumab and capecitabine are the combination partners, while tucatinib is a small-molecule drug. Trastuzumab biosimilars could affect regimen economics without directly invalidating or infringing the tucatinib method claims. How does tucatinib compare with competing HER2 brain-metastases therapies?
The patent does not prevent physicians from using competing HER2-directed therapies. It targets the specific tucatinib-trastuzumab-capecitabine regimen. What licensing and ownership issues matter?Tucatinib was associated with Cascadian Therapeutics before Seattle Genetics acquired Cascadian in 2018 for approximately $614 million.[6] Seattle Genetics later changed its corporate name to Seagen. Pfizer completed its acquisition of Seagen in 2023.[7] Ownership history matters for:
The commercial owner of Tukysa and the patent owner of each member of the tucatinib patent family should be confirmed separately. Patent ownership can differ from NDA sponsorship and brand ownership. Key Takeaways
FAQsDoes US 11,504,370 cover Tukysa tablets by themselves?No. The supplied claims require administration of tucatinib in combination with trastuzumab and capecitabine. The patent does not claim the tablet as a standalone product. Does the patent cover tucatinib used with trastuzumab deruxtecan?Not on the supplied claim language. The claims require trastuzumab and capecitabine. Trastuzumab deruxtecan is a different product and does not satisfy those express limitations. Can a generic tucatinib applicant omit brain-metastases language from its label?A label carve-out may reduce method-of-use exposure, but liability can still depend on the remaining indication, promotional conduct and foreseeable encouraged use. FDA labeling strategy must be analyzed against each Orange Book-listed use code. Are trastuzumab biosimilars blocked by this patent?No. The patent does not claim trastuzumab itself. A trastuzumab biosimilar may be used in a regimen that potentially falls within the method claims, but the patent’s primary enforcement target would generally be conduct involving the patented tucatinib regimen. Does claim 8 cover HER2-negative breast cancer?On its face, claim 8 does not expressly require HER2-positive disease. Claims 1 and 9 onward impose HER2-related restrictions. The validity and construction of claim 8 would depend on the patent specification, prosecution history and factual treatment context. References
More… ↓ |
Drugs Protected by US Patent 11,504,370
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER | ⤷ Start Trial | ||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,504,370
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013234921 | ⤷ Start Trial | |||
| Australia | 2017272232 | ⤷ Start Trial | |||
| Australia | 2019203618 | ⤷ Start Trial | |||
| Australia | 2021261849 | ⤷ Start Trial | |||
| Canada | 2867723 | ⤷ Start Trial | |||
| Chile | 2014002497 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
